Cargando…
Sarcopenia: An underlying treatment target during the COVID-19 pandemic
The role of skeletal muscle mass in modulating immune response and supporting metabolic stress has been increasingly confirmed. Patients with sarcopenia, characterized by reduced muscle mass and muscle strength, were reported to have poor immune response and metabolic stress when facing acute infect...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833321/ https://www.ncbi.nlm.nih.gov/pubmed/33421827 http://dx.doi.org/10.1016/j.nut.2020.111104 |
_version_ | 1783642038756966400 |
---|---|
author | Wang, Pei-yu Li, Yin Wang, Qin |
author_facet | Wang, Pei-yu Li, Yin Wang, Qin |
author_sort | Wang, Pei-yu |
collection | PubMed |
description | The role of skeletal muscle mass in modulating immune response and supporting metabolic stress has been increasingly confirmed. Patients with sarcopenia, characterized by reduced muscle mass and muscle strength, were reported to have poor immune response and metabolic stress when facing acute infection, major surgeries, and other attacks. Based on empirical data, patients with sarcopenia are speculated to have increased infection rates and dismal prognoses amid the current 2019 novel coronavirus disease (COVID-19) epidemic. COVID-19 infection also aggravates sarcopenia because of the increased muscle wasting caused by systematic inflammation and the reduced physical activity and inadequate nutrient intake caused by social isolation. Notably, the interventions targeting skeletal muscle are anticipated to break the vicious circle and benefit the treatment of both conditions. We recommend sarcopenia assessment for populations with advanced age, inactivity, chronic disease, cancers, and nutritional deficiency. Patients with sarcopenia and COVID-19 infection need intensive care and aggressive treatments. The provision of at-home physical activities together with protein supplementation is anticipated to reverse sarcopenia and promote the prevention and treatment of COVID-19. The recommended protocols on nutritional support and physical activities are provided in detail. |
format | Online Article Text |
id | pubmed-7833321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78333212021-01-26 Sarcopenia: An underlying treatment target during the COVID-19 pandemic Wang, Pei-yu Li, Yin Wang, Qin Nutrition Hypothesis The role of skeletal muscle mass in modulating immune response and supporting metabolic stress has been increasingly confirmed. Patients with sarcopenia, characterized by reduced muscle mass and muscle strength, were reported to have poor immune response and metabolic stress when facing acute infection, major surgeries, and other attacks. Based on empirical data, patients with sarcopenia are speculated to have increased infection rates and dismal prognoses amid the current 2019 novel coronavirus disease (COVID-19) epidemic. COVID-19 infection also aggravates sarcopenia because of the increased muscle wasting caused by systematic inflammation and the reduced physical activity and inadequate nutrient intake caused by social isolation. Notably, the interventions targeting skeletal muscle are anticipated to break the vicious circle and benefit the treatment of both conditions. We recommend sarcopenia assessment for populations with advanced age, inactivity, chronic disease, cancers, and nutritional deficiency. Patients with sarcopenia and COVID-19 infection need intensive care and aggressive treatments. The provision of at-home physical activities together with protein supplementation is anticipated to reverse sarcopenia and promote the prevention and treatment of COVID-19. The recommended protocols on nutritional support and physical activities are provided in detail. Elsevier Inc. 2021-04 2020-12-05 /pmc/articles/PMC7833321/ /pubmed/33421827 http://dx.doi.org/10.1016/j.nut.2020.111104 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Hypothesis Wang, Pei-yu Li, Yin Wang, Qin Sarcopenia: An underlying treatment target during the COVID-19 pandemic |
title | Sarcopenia: An underlying treatment target during the COVID-19 pandemic |
title_full | Sarcopenia: An underlying treatment target during the COVID-19 pandemic |
title_fullStr | Sarcopenia: An underlying treatment target during the COVID-19 pandemic |
title_full_unstemmed | Sarcopenia: An underlying treatment target during the COVID-19 pandemic |
title_short | Sarcopenia: An underlying treatment target during the COVID-19 pandemic |
title_sort | sarcopenia: an underlying treatment target during the covid-19 pandemic |
topic | Hypothesis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833321/ https://www.ncbi.nlm.nih.gov/pubmed/33421827 http://dx.doi.org/10.1016/j.nut.2020.111104 |
work_keys_str_mv | AT wangpeiyu sarcopeniaanunderlyingtreatmenttargetduringthecovid19pandemic AT liyin sarcopeniaanunderlyingtreatmenttargetduringthecovid19pandemic AT wangqin sarcopeniaanunderlyingtreatmenttargetduringthecovid19pandemic |